Bimetallic Mesoporous MCM-41 Nanoparticles with Ta/(Ti, V, Co, Nb) with Catalytic and Photocatalytic Properties.

Bimetallic (Ta/Ti, V, Co, Nb) mesoporous MCM-41 nanoparticles were obtained by direct synthesis and hydrothermal treatment. The obtained mesoporous materials were characterized by XRD, XRF, N adsorption/desorption, SEM, TEM, XPS, Raman, UV-Vis, and PL spectroscopy. A more significant effect was observed on the mesoporous structure, typically for MCM-41, and on optic properties if the second metal (Ti, Co) did not belong to the same Vb group with Ta as V and Nb.

Improved Photocatalytic Activity of Dion-Jacobson-Type Tantalate Perovskites Modified with FeCl.

A rapid and feasible approach was used to develop visible-light-driven-type Dion-Jacobson perovskites by the modification of the RbLaTaO host (RbLTO) with FeCl through the molten salt route. X-ray diffraction (XRD) characterization showed that FeCl-modified layered perovskite (e.g.

Porphyrin Photosensitizers into Polysaccharide-Based Biopolymer Hydrogels for Topical Photodynamic Therapy: Physicochemical and Pharmacotechnical Assessments.

Photodynamic therapy (PDT) is an emerging treatment modality that utilizes light-sensitive compounds, known as photosensitizers, to produce reactive oxygen species (ROS) that can selectively destroy malignant or diseased tissues upon light activation. This study investigates the incorporation of two porphyrin structures, 5-(4-hydroxy-3-methoxyphenyl)-10,15,20-tris-(4-acetoxy-3-methoxyphenyl) porphyrin (P2.2.

The development of an innovative method to improve the dissolution performance of rivaroxaban.

Recent advancements in the formulation of solid dosage forms involving active ingredient-cyclodextrin complexes have garnered considerable attention in pharmaceutical research. While previous studies predominantly focused on incorporating these complexes into solid states, issues regarding incomplete inclusion prompted the exploration of novel methods. In this study, we aimed to develop an innovative approach to integrate liquid-state drug-cyclodextrin inclusion complexes into solid dosage forms.